Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Haloperidol | 15 | 2019 | 26 | 4.490 |
Why?
|
| Antipsychotic Agents | 10 | 2020 | 68 | 3.780 |
Why?
|
| Antifungal Agents | 10 | 2016 | 148 | 2.880 |
Why?
|
| Receptors, Dopamine D2 | 8 | 2020 | 73 | 2.860 |
Why?
|
| Azepines | 6 | 2019 | 17 | 2.720 |
Why?
|
| Quinolines | 12 | 2013 | 64 | 2.630 |
Why?
|
| Pyridines | 5 | 2021 | 116 | 2.530 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 5 | 2021 | 13 | 2.420 |
Why?
|
| Piperazines | 5 | 2021 | 111 | 2.330 |
Why?
|
| Structure-Activity Relationship | 26 | 2021 | 409 | 2.180 |
Why?
|
| Receptors, Serotonin | 5 | 2021 | 22 | 2.140 |
Why?
|
| Receptors, sigma | 6 | 2019 | 15 | 1.830 |
Why?
|
| Fungi | 7 | 2016 | 89 | 1.770 |
Why?
|
| Indoles | 9 | 2014 | 158 | 1.690 |
Why?
|
| Ligands | 11 | 2021 | 349 | 1.250 |
Why?
|
| Isoquinolines | 2 | 2019 | 45 | 1.220 |
Why?
|
| Molecular Structure | 14 | 2021 | 492 | 1.110 |
Why?
|
| Behavior, Animal | 3 | 2020 | 314 | 1.100 |
Why?
|
| Alkaloids | 8 | 2008 | 39 | 1.080 |
Why?
|
| Apomorphine | 4 | 2020 | 13 | 1.030 |
Why?
|
| Quinolinium Compounds | 2 | 2013 | 7 | 0.930 |
Why?
|
| Catalepsy | 5 | 2019 | 8 | 0.890 |
Why?
|
| Chromatography, High Pressure Liquid | 5 | 2019 | 421 | 0.860 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2021 | 1039 | 0.790 |
Why?
|
| Drug Design | 5 | 2013 | 162 | 0.780 |
Why?
|
| Serotonin Antagonists | 1 | 2021 | 23 | 0.760 |
Why?
|
| Animals | 30 | 2020 | 15081 | 0.760 |
Why?
|
| Butyrophenones | 3 | 2011 | 5 | 0.760 |
Why?
|
| Anti-Bacterial Agents | 3 | 2013 | 352 | 0.730 |
Why?
|
| Microbial Sensitivity Tests | 8 | 2016 | 201 | 0.710 |
Why?
|
| Phenylcarbamates | 1 | 2019 | 2 | 0.700 |
Why?
|
| Amylose | 1 | 2019 | 5 | 0.700 |
Why?
|
| Indenes | 1 | 2019 | 4 | 0.700 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2016 | 21 | 0.560 |
Why?
|
| Receptors, Dopamine D4 | 2 | 2014 | 14 | 0.540 |
Why?
|
| Anti-Infective Agents | 2 | 2006 | 64 | 0.520 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 803 | 0.510 |
Why?
|
| Bacteria | 4 | 2013 | 255 | 0.510 |
Why?
|
| Tropanes | 1 | 2014 | 6 | 0.490 |
Why?
|
| Vero Cells | 5 | 2013 | 93 | 0.490 |
Why?
|
| Rats | 11 | 2019 | 3483 | 0.490 |
Why?
|
| Acrylamides | 1 | 2014 | 8 | 0.480 |
Why?
|
| Psychology, Experimental | 1 | 2014 | 2 | 0.480 |
Why?
|
| Dopamine Antagonists | 1 | 2014 | 44 | 0.480 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2019 | 1618 | 0.470 |
Why?
|
| Cryptococcus | 1 | 2013 | 5 | 0.460 |
Why?
|
| Sulfhydryl Compounds | 1 | 2013 | 47 | 0.450 |
Why?
|
| Mice | 9 | 2020 | 5913 | 0.420 |
Why?
|
| Stereoisomerism | 5 | 2019 | 167 | 0.420 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2012 | 14 | 0.420 |
Why?
|
| Benzothiazoles | 1 | 2012 | 21 | 0.420 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2013 | 107 | 0.420 |
Why?
|
| Biological Products | 1 | 2013 | 71 | 0.420 |
Why?
|
| Small Molecule Libraries | 1 | 2012 | 45 | 0.410 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 50 | 0.410 |
Why?
|
| Carbolines | 1 | 2011 | 15 | 0.390 |
Why?
|
| Humans | 19 | 2021 | 37093 | 0.350 |
Why?
|
| Indole Alkaloids | 7 | 2013 | 11 | 0.340 |
Why?
|
| Clozapine | 4 | 2014 | 17 | 0.330 |
Why?
|
| Antioxidants | 1 | 2012 | 416 | 0.330 |
Why?
|
| Piperidines | 3 | 2004 | 77 | 0.290 |
Why?
|
| Cell Survival | 3 | 2019 | 864 | 0.280 |
Why?
|
| Butanones | 1 | 2006 | 5 | 0.280 |
Why?
|
| Oxidative Stress | 1 | 2012 | 938 | 0.280 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 2010 | 289 | 0.280 |
Why?
|
| Pyrrolidines | 1 | 2006 | 29 | 0.270 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2003 | 9 | 0.240 |
Why?
|
| Basal Ganglia Diseases | 1 | 2003 | 6 | 0.240 |
Why?
|
| Male | 10 | 2020 | 20025 | 0.230 |
Why?
|
| Protein Binding | 3 | 2019 | 972 | 0.220 |
Why?
|
| Radioligand Assay | 4 | 2004 | 66 | 0.220 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 1993 | 62 | 0.220 |
Why?
|
| Molecular Probes | 1 | 2002 | 23 | 0.210 |
Why?
|
| Carboxylic Ester Hydrolases | 2 | 2014 | 52 | 0.210 |
Why?
|
| Binding Sites | 3 | 2016 | 651 | 0.200 |
Why?
|
| Carrier Proteins | 1 | 2003 | 305 | 0.200 |
Why?
|
| Stereotyped Behavior | 3 | 2008 | 22 | 0.200 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2019 | 113 | 0.190 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 1371 | 0.180 |
Why?
|
| Nitrogen | 1 | 2000 | 71 | 0.170 |
Why?
|
| Tissue Distribution | 2 | 2019 | 207 | 0.170 |
Why?
|
| Cisplatin | 1 | 2019 | 72 | 0.160 |
Why?
|
| Brain | 3 | 2019 | 1346 | 0.160 |
Why?
|
| Schizophrenia | 1 | 2019 | 76 | 0.160 |
Why?
|
| Platelet Aggregation | 2 | 1993 | 19 | 0.140 |
Why?
|
| Isomerism | 2 | 2006 | 63 | 0.140 |
Why?
|
| Dopamine Agents | 1 | 2016 | 25 | 0.140 |
Why?
|
| Opportunistic Infections | 1 | 2016 | 10 | 0.140 |
Why?
|
| Mycoses | 1 | 2016 | 30 | 0.130 |
Why?
|
| Cryptococcus neoformans | 2 | 2010 | 56 | 0.130 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 1993 | 31 | 0.130 |
Why?
|
| Cell Line, Tumor | 2 | 2019 | 2231 | 0.120 |
Why?
|
| Plasmodium falciparum | 2 | 2006 | 135 | 0.120 |
Why?
|
| Receptor, Serotonin, 5-HT2B | 1 | 2014 | 6 | 0.120 |
Why?
|
| Binding, Competitive | 1 | 2014 | 111 | 0.120 |
Why?
|
| Benzodiazepines | 1 | 2014 | 15 | 0.120 |
Why?
|
| Candida albicans | 2 | 2010 | 164 | 0.120 |
Why?
|
| Mitosporic Fungi | 2 | 2005 | 4 | 0.120 |
Why?
|
| Cricetulus | 1 | 2014 | 80 | 0.120 |
Why?
|
| CHO Cells | 1 | 2014 | 124 | 0.120 |
Why?
|
| Kinetics | 3 | 2008 | 708 | 0.120 |
Why?
|
| Posture | 1 | 2014 | 58 | 0.120 |
Why?
|
| Cricetinae | 1 | 2014 | 238 | 0.120 |
Why?
|
| Basidiomycota | 1 | 2013 | 11 | 0.120 |
Why?
|
| Hand Strength | 1 | 2014 | 34 | 0.120 |
Why?
|
| Least-Squares Analysis | 1 | 2013 | 43 | 0.120 |
Why?
|
| Pyridinium Compounds | 1 | 1993 | 27 | 0.120 |
Why?
|
| Arachidonic Acid | 1 | 1993 | 35 | 0.120 |
Why?
|
| Amides | 1 | 2014 | 68 | 0.110 |
Why?
|
| Blood Platelets | 1 | 1993 | 77 | 0.110 |
Why?
|
| Collagen | 1 | 1993 | 172 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 111 | 0.110 |
Why?
|
| Cyclic AMP | 1 | 1993 | 131 | 0.100 |
Why?
|
| Cyclization | 2 | 2010 | 48 | 0.100 |
Why?
|
| Receptors, Dopamine | 1 | 2011 | 25 | 0.100 |
Why?
|
| Indicators and Reagents | 2 | 2006 | 58 | 0.100 |
Why?
|
| Avoidance Learning | 1 | 2012 | 62 | 0.100 |
Why?
|
| Substrate Specificity | 1 | 2012 | 212 | 0.100 |
Why?
|
| Motor Activity | 1 | 2014 | 418 | 0.100 |
Why?
|
| Drug Discovery | 1 | 2012 | 82 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 9 | 0.100 |
Why?
|
| Aspergillus fumigatus | 1 | 2010 | 10 | 0.100 |
Why?
|
| Protein Methyltransferases | 1 | 2010 | 6 | 0.090 |
Why?
|
| Protein Prenylation | 1 | 2010 | 10 | 0.090 |
Why?
|
| Droperidol | 1 | 2010 | 3 | 0.090 |
Why?
|
| Bromocriptine | 1 | 2010 | 7 | 0.090 |
Why?
|
| Liver | 1 | 1993 | 479 | 0.090 |
Why?
|
| Candidiasis | 1 | 2010 | 84 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 935 | 0.090 |
Why?
|
| Calcium | 1 | 1993 | 480 | 0.090 |
Why?
|
| Cell Death | 2 | 2014 | 267 | 0.090 |
Why?
|
| Fibroblasts | 1 | 2011 | 272 | 0.080 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 162 | 0.080 |
Why?
|
| Lethal Dose 50 | 1 | 2008 | 30 | 0.080 |
Why?
|
| Vasodilator Agents | 1 | 2008 | 56 | 0.080 |
Why?
|
| Antiprotozoal Agents | 1 | 2008 | 30 | 0.080 |
Why?
|
| Antiparasitic Agents | 1 | 2006 | 8 | 0.070 |
Why?
|
| Leishmania donovani | 1 | 2006 | 17 | 0.070 |
Why?
|
| Chemistry, Physical | 1 | 2006 | 45 | 0.070 |
Why?
|
| Chemical Phenomena | 1 | 2006 | 54 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 160 | 0.070 |
Why?
|
| Antimalarials | 1 | 2006 | 55 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 83 | 0.060 |
Why?
|
| Thioxanthenes | 1 | 2004 | 1 | 0.060 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2004 | 34 | 0.060 |
Why?
|
| Dopamine Agonists | 1 | 2003 | 30 | 0.060 |
Why?
|
| Rabbits | 2 | 1993 | 283 | 0.050 |
Why?
|
| Cell Line | 1 | 2006 | 1354 | 0.050 |
Why?
|
| Psychomotor Performance | 1 | 2003 | 136 | 0.050 |
Why?
|
| Guinea Pigs | 2 | 2000 | 145 | 0.050 |
Why?
|
| Alkylation | 2 | 1999 | 11 | 0.050 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1999 | 41 | 0.040 |
Why?
|
| Fatty Acids | 1 | 1999 | 127 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 1999 | 204 | 0.040 |
Why?
|
| Temperature | 1 | 1999 | 286 | 0.040 |
Why?
|
| Models, Chemical | 1 | 1999 | 207 | 0.040 |
Why?
|
| Models, Biological | 1 | 2000 | 677 | 0.040 |
Why?
|
| Cell Membrane | 2 | 1994 | 381 | 0.030 |
Why?
|
| Methylation | 2 | 2010 | 113 | 0.030 |
Why?
|
| Amines | 1 | 1994 | 39 | 0.030 |
Why?
|
| Oxalates | 1 | 1993 | 3 | 0.030 |
Why?
|
| Calcimycin | 1 | 1993 | 12 | 0.030 |
Why?
|
| Rana pipiens | 1 | 1993 | 62 | 0.030 |
Why?
|
| Thrombin | 1 | 1993 | 25 | 0.030 |
Why?
|
| 1-Methyl-4-phenylpyridinium | 1 | 1993 | 30 | 0.030 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 1993 | 13 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 1993 | 233 | 0.030 |
Why?
|
| Imidazoles | 1 | 1993 | 126 | 0.030 |
Why?
|
| Reference Standards | 1 | 2010 | 52 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2014 | 808 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2010 | 141 | 0.020 |
Why?
|
| Drug Stability | 1 | 2010 | 116 | 0.020 |
Why?
|
| Swine | 1 | 2010 | 184 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 389 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1198 | 0.020 |
Why?
|
| Time Factors | 1 | 1993 | 1742 | 0.020 |
Why?
|
| Female | 1 | 1993 | 20969 | 0.010 |
Why?
|
| Radioisotope Dilution Technique | 1 | 1985 | 3 | 0.000 |
Why?
|
| Iodine Radioisotopes | 1 | 1985 | 35 | 0.000 |
Why?
|
| Plants, Medicinal | 1 | 1985 | 68 | 0.000 |
Why?
|